Unrelated Cord Blood Transplantation in Adult and Pediatric Acute Lymphoblastic Leukemia: Effect of Minimal Residual Disease on Relapse and Survival

Biology of Blood and Marrow Transplantation

Volumn 18, Issue 6, 2012, Pages 963-968

  Bachanova, Veronika ^a   Burke, Michael J ^a   Yohe, Sophia ^b   Cao, Qing ^c   Sandhu, Karamjeet ^d   Singleton, Timothy P ^b   Brunstein, Claudio G ^a   Wagner, John E ^a   Verneris, Michael R ^a   Weisdorf, Daniel J ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d HENNEPIN COUNTY MEDICAL CENTER   (United States)

Author keywords

Acute Leukemia; Allogeneic transplant; Flow cytometry; Umbilical cord blood transplant

Indexed keywords

CYCLOSPORIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; CANCER PATIENT; CANCER RELAPSE; CANCER SURVIVAL; CHILD; CHILDHOOD LEUKEMIA; DISEASE FREE SURVIVAL; FEMALE; FLOW CYTOMETRY; GRAFT VERSUS HOST REACTION; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; PHILADELPHIA 1 CHROMOSOME; PRESCHOOL CHILD; PROSPECTIVE STUDY; SCHOOL CHILD; UMBILICAL CORD BLOOD; UMBILICAL CORD BLOOD TRANSPLANTATION;

ADOLESCENT; ADULT; AGE FACTORS; ANTINEOPLASTIC AGENTS; CHILD; CHILD, PRESCHOOL; CORD BLOOD STEM CELL TRANSPLANTATION; CYCLOSPORINE; DISEASE-FREE SURVIVAL; FEMALE; FETAL BLOOD; GRAFT VS HOST DISEASE; HUMANS; INFANT; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; NEOPLASM, RESIDUAL; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RECURRENCE; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; UNRELATED DONORS;

EID: 84860796306     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2012.02.012     Document Type: Article

References (28)

1. Goldstone A.H., Richards S.M., Lazarus H.M., et al. In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993). Blood 2008, 111:1827-1833.
2. Weisdorf D., Forman S. Allogeneic hematopoietic stem cell transplantation for adult acute lymphoblastic leukemia. Cancer Treat Res 2009, 144:1-14.
3. Kiehl M.G., Kraut L., Schwerdtfeger R., et al. Outcome of allogeneic hematopoietic stem-cell transplantation in adult patients with acute lymphoblastic leukemia: no difference in related compared with unrelated transplant in first complete remission. J Clin Oncol 2004, 22:2816-2825.
4. Eapen M., Rubinstein P., Zhang M.J., et al. Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukaemia: a comparison study. Lancet 2007, 369:1947-1954.
5. Knechtli C.J., Goulden N.J., Hancock J.P., et al. Minimal residual disease status before allogeneic bone marrow transplantation is an important determinant of successful outcome for children and adolescents with acute lymphoblastic leukemia. Blood 1998, 92:4072-4079.
6. Bader P., Kreyenberg H., Henze G.H., et al. Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM Study Group. J Clin Oncol 2009, 27:377-384.
7. Campana D. Role of minimal residual disease monitoring in adult and pediatric acute lymphoblastic leukemia. Hematol Oncol Clin North Am 2009, 23:1083-1098.
8. Goulden N., Bader P., Van Der Velden V., et al. Minimal residual disease prior to stem cell transplant for childhood acute lymphoblastic leukaemia. Br J Haematol 2003, 122:24-29.
9. Sramkova L., Muzikova K., Fronkova E., et al. Detectable minimal residual disease before allogeneic hematopoietic stem cell transplantation predicts extremely poor prognosis in children with acute lymphoblastic leukemia. Pediatr Blood Cancer 2007, 48:93-100.
10. Bassan R., Spinelli O., Oldani E., et al. Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL). Blood 2009, 113:4153-4162.
11. Patel B., Rai L., Buck G., et al. Minimal residual disease is a significant predictor of treatment failure in non-T-lineage adult acute lymphoblastic leukaemia: final results of the international trial UKALL XII/ECOG2993. Br J Haematol 2010, 148:80-89.
12. Spinelli O., Peruta B., Tosi M., et al. Clearance of minimal residual disease after allogeneic stem cell transplantation and the prediction of the clinical outcome of adult patients with high-risk acute lymphoblastic leukemia. Haematologica 2007, 92:612-618.
13. Mortuza F.Y., Papaioannou M., Moreira I.M., et al. Minimal residual disease tests provide an independent predictor of clinical outcome in adult acute lymphoblastic leukemia. J Clin Oncol 2002, 20:1094-1104.
14. Miglino M., Berisso G., Grasso R., et al. Allogeneic bone marrow transplantation (BMT) for adults with acute lymphoblastic leukemia (ALL): predictive role of minimal residual disease monitoring on relapse. Bone Marrow Transplant 2002, 30:579-585.
15. Foster J.H., Hawkins D.S., Loken M.R., et al. Minimal residual disease detected prior to hematopoietic cell transplantation. Pediatr Blood Cancer 2011, 57:163-165.
16. Irving J., Jesson J., Virgo P., et al. Establishment and validation of a standard protocol for the detection of minimal residual disease in B lineage childhood acute lymphoblastic leukemia by flow cytometry in a multi-center setting. Haematologica 2009, 94:870-874.
17. Jmili N.B., Souguir S., Yacoub S., et al. Study of antigenic profile of blasts in acute lymphoblastic leukaemia: flow cytometric analysis of 152 cases. Ann Biol Clin (Paris) 2009, 67:543-551.
18. Verneris M.R., Brunstein C.G., Barker J., et al. Relapse risk after umbilical cord blood transplantation: enhanced graft versus leukemia effect in recipients of 2 units. Blood 2009, 114(19):4293-4299.
19. Brunstein C.G., Barker J.N., Weisdorf D.J., et al. Umbilical cord blood transplantation after nonmyeloablative conditioning: impact on transplantation outcomes in 110 adults with hematologic disease. Blood 2007, 110:3064-3070.
20. Bjorklund E., Matinlauri I., Tierens A., et al. Quality control of flow cytometry data analysis for evaluation of minimal residual disease in bone marrow from acute leukemia patients during treatment. J Pediatr Hematol Oncol 2009, 31:406-415.
21. Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958, 53:457-481.
22. Lin D.Y. Non-parametric inference for cumulative incidence functions in competing risks studies. Stat Med 1997, 16:901-910.
23. Bachanova V., Weisdorf D. Unrelated donor allogeneic transplantation for adult acute lymphoblastic leukemia: a review. Bone Marrow Transplant 2008, 41:455-464.
24. Marks D.I., Aversa F., Lazarus H.M. Alternative donor transplants for adult acute lymphoblastic leukaemia: a comparison of the three major options. Bone Marrow Transplant 2006, 38:467-475.
25. Tomblyn M.B., Arora M., Baker K.S., et al. Myeloablative hematopoietic cell transplantation for acute lymphoblastic leukemia: analysis of graft sources and long-term outcome. J Clin Oncol 2009, 27:3634-3641.
26. Coustan-Smith E., Song G., Clark C., et al. New markers for minimal residual disease detection in acute lymphoblastic leukemia. Blood 2011, 117:6267-6276.
27. Bruggemann M., Schrauder A., Raff T., et al. Standardized MRD quantification in European ALL trials: proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008. Leukemia 2010, 24:521-535.
28. Topp M.S., Kufer P., Gokbuget N., et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol 2011, 29:2493-2498.